- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02782546
Terapia adoptiva de células NK similares a la memoria inducida por citocinas después del trasplante de células hematopoyéticas de donantes haploidénticos
Un estudio de fase II de la terapia adoptiva de células NK similares a la memoria inducida por citoquinas después del trasplante de células hematopoyéticas de donantes haploidénticos
This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from <10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort).
A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (>60% any grades or >30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Recipient Inclusion Criteria:
-
Refractory AML without complete remission (CR) after 2 or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one or more cycles of re-induction therapy. Standard dose 10-day decitabine (20 mg/m2 daily IV x 10 days) or 7-day azacitidine (75-100 mg/m2 daily SC/IV x 7 days) will be considered as one cycle of induction therapy.
-
At least 18 years of age
-
Available HLA-haploidentical donor that meets the criteria in the protocol
-
Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.
-
Karnofsky performance status > 60 %
-
Adequate organ function as defined below:
- Total bilirubin < 2 mg/dl
- AST(SGOT)/ALT(SGPT) < 3.0 x IULN
- Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m2 by Cockcroft-Gault Formula
- Oxygen saturation ≥90% on room air and adjusted DLCO of at least 40%
- Ejection fraction ≥40%
-
Able to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on Day -3
-
Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the DLT evaluation period.
-
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Recipient Exclusion Criteria:
- Relapsed after allogeneic transplantation.
- Circulating blast count >30,000/uL by morphology or flow cytometry (cyto-reductive therapies including leukapheresis or hydroxyurea are allowed).
- Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.
- Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of >5000 as assessed by the single antigen bead assay, < 6 weeks prior to starting transplant conditioning
- Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.
- New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections)
- Known hypersensitivity to one or more of the study agents
- Received any investigational drugs within the 14 days prior to the first day of transplant conditioning
- Pregnant and/or breastfeeding
Donor Inclusion Criteria:
- Related donor (sibling, offspring, or offspring of sibling)
- At least 18 years of age
- HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus.
- In general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
- Ability to understand and willingness to sign an IRB approved written informed consent document
Donor Exclusion Criteria:
- Positive for hepatitis, HTLV, or HIV infection
- Pregnant and/or breastfeeding
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Recipient
|
-Day 0
Otros nombres:
-GVHD prophylaxis
Otros nombres:
-GVHD prophylaxis
Otros nombres:
-Continue until neutrophil engraftment as per institutional guidelines
Otros nombres:
-Day +7 -Start approximately 4 hours after CIML NK cell infusion |
|
Experimental: Donor
|
-Day +6 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)
Periodo de tiempo: 1 year post transplantation
|
-LFS is defined as the time from achievement of complete remission (CR) to the time of relapse, death in remission, or last follow-up. |
1 year post transplantation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)
Periodo de tiempo: 3 months post transplantation
|
-LFS is defined as the time from achievement of CR to the time of relapse, death in remission, or last follow-up. |
3 months post transplantation
|
|
Kaplan-Meier Estimate of Overall Survival (OS)
Periodo de tiempo: 1 year post transplantation
|
-OS is defined as the time from the date of Day 0 until death from any cause. |
1 year post transplantation
|
|
Number of Recipients With Relapse Who Are Found to be CR (Complete Remission)
Periodo de tiempo: Day 28 post transplantation
|
-CR: Morphologically leukemia free state (i.e. bone marrow with <5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions. |
Day 28 post transplantation
|
|
Complete Remission (CR) Rate
Periodo de tiempo: Day 28 post transplantation
|
CR: Morphologically leukemia free state (i.e. bone marrow with <5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions |
Day 28 post transplantation
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Amanda Cashen, M.D., Washington University School of Medicine
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Leucemia Mieloide
- Leucemia
- Enfermedades hemic y linfáticas
- Leucemia Mieloide Aguda
- Péptidos
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Técnicas de investigación
- Terapéutica
- Ácidos grasos
- Lípidos
- Técnicas de laboratorio clínico
- Técnicas citológicas
- Factores biológicos
- Carbohidratos
- Ácidos, acíclico
- Ácidos carboxílicos
- Macrólidos
- Lactonas
- Péptidos de señalización intercelular y proteínas
- Glicoproteínas
- Glucoconjugados
- Terapia biológica
- Citaféresis
- Extracción de componentes sanguíneos
- Procedimientos de reducción de leucocitos
- Separación celular
- Factores estimulantes de colonias
- Factores de crecimiento de células hematopoyéticas
- Citocinas
- Caproates
- Ácido micofenólico
- Tacrolimús
- Leucaféresis
- Alt-803
- Factor estimulador de colonias de granulocitos
Otros números de identificación del estudio
- 201610088
- 2P50CA171963-06 (Subvención/contrato del NIH de EE. UU.)
- 1P50CA171963-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .